Want to see AU:AVE full AI Analyst Report?
Top Page
Avecho Biotechnology Limited
(Sydney:AVE)
Select Model
Select Model
Rating:49Neutral
Price Target:
AU$0.02
▲(90.00% Upside)
Action:Reiterated
Date:10/01/26
The score is held back primarily by ongoing losses and equity erosion despite improving revenue and a recent shift to positive operating/free cash flow. Technicals are mildly supportive (price above the 100-day average and slightly positive MACD), but valuation remains weak due to negative earnings and no dividend yield.
Positive Factors
Revenue rebound
Accelerating revenue growth indicates improving demand and commercial traction for Avecho’s products and TPM-based platform. If maintained, stronger top-line momentum can support operating leverage, broaden the company’s market position, and provide a better base for future partnering or product expansion.
Negative Factors
Persistent losses
Continued operating and net losses show that improved revenue has not yet translated into a sustainable profitable business model. Persistent losses can consume capital, restrict investment capacity, and make future growth dependent on continued funding until margins improve materially.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound
Accelerating revenue growth indicates improving demand and commercial traction for Avecho’s products and TPM-based platform. If maintained, stronger top-line momentum can support operating leverage, broaden the company’s market position, and provide a better base for future partnering or product expansion.
Read all positive factors
Avecho Biotechnology Limited (AVE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$73.41M
Dividend YieldN/A
Average Volume (3M)3.41M
Price to Earnings (P/E)―
Beta (1Y)1.22
Revenue Growth-46.59%
EPS Growth9.09%
CountryAU
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,863,725,800
10 Day Avg. Volume2,373,856
30 Day Avg. Volume3,405,278
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)18.85
Price to Sales (P/S)23.75
P/FCF Ratio26.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Avecho Biotechnology Limited Business Overview & Revenue Model
Company Description
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It ope...
How the Company Makes Money
Avecho makes money primarily by commercialising products and technologies based on its TPM delivery platform. Key revenue streams include: (1) consumer health product sales, where Avecho generates revenue from selling finished products that use it...
Avecho Biotechnology Limited Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
52
Neutral
Cash Flow
57
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.02M | 1.24M | 1.13M | 473.55K | 1.13M | 793.60K |
| Gross Profit | 543.05K | 751.29K | 671.93K | -43.80K | 793.12K | 507.94K |
| EBITDA | -7.79M | -5.87M | -2.92M | -3.24M | -2.11M | -2.98M |
| Net Income | -3.66M | -4.42M | -3.12M | -3.44M | -2.34M | -3.42M |
Balance Sheet | ||||||
| Total Assets | 8.41M | 7.11M | 5.00M | 7.32M | 3.35M | 5.25M |
| Cash, Cash Equivalents and Short-Term Investments | 6.61M | 4.66M | 2.37M | 5.50M | 1.47M | 3.26M |
| Total Debt | 227.54K | 14.47K | 1.08M | 175.15K | 246.07K | 93.91K |
| Total Liabilities | 6.50M | 5.55M | 1.73M | 941.54K | 920.66K | 709.36K |
| Stockholders Equity | 1.91M | 1.56M | 3.27M | 6.38M | 2.42M | 4.54M |
Cash Flow | ||||||
| Free Cash Flow | -3.48M | 1.10M | -3.97M | -3.18M | -1.72M | -3.30M |
| Operating Cash Flow | -3.48M | 1.10M | -3.97M | -3.18M | -1.67M | -3.10M |
| Investing Cash Flow | -2.00K | 0.00 | -15.73K | 0.00 | -53.12K | -202.82K |
| Financing Cash Flow | 4.16M | 1.19M | 854.59K | 7.22M | -78.22K | 4.69M |
Avecho Biotechnology Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$73.41M | -13.33 | -211.39% | ― | -46.59% | 9.09% | |
47 Neutral | AU$153.48M | -1.61 | -1189.87% | ― | 53.78% | -206.24% | |
45 Neutral | AU$82.36M | -9.28 | -44.93% | ― | ― | 25.27% | |
43 Neutral | AU$50.11M | -0.63 | -98.86% | ― | ― | -27.73% | |
43 Neutral | AU$99.38M | -6.08 | 84.67% | ― | ― | 42.51% | |
41 Neutral | AU$23.60M | -0.13 | -414.10% | ― | ― | -2.15% |
* Healthcare Sector Average
AU:AVE
Avecho Biotechnology Limited
0.02
<0.01
90.00%
AU:IMU
Imugene
0.04
-0.26
-86.00%
AU:PAR
Paradigm Biopharmaceuticals
0.25
-0.09
-26.87%
AU:IMM
Immutep Ltd
0.03
-0.23
-86.92%
AU:PTX
Prescient Therapeutics Limited
0.07
0.03
59.52%
AU:RCE
Recce Pharmaceuticals Ltd.
0.32
-0.10
-24.10%
Avecho Biotechnology Limited Corporate Events
Avecho Advances Phase III CBD Insomnia Trial Ahead of ASX SMIDcaps Presentation
Sep 22, 2026
Avecho Biotechnology Limited will present at the ASX SMIDcaps Conference, where CEO Dr Paul Gavin will update investors on the company’s Phase III trial of its CBD TPM soft-gel capsule for insomnia and outline planned activities over the nex...
Avecho resumes final recruitment for pivotal Phase III insomnia trial
Aug 31, 2026
Avecho Biotechnology has restarted recruitment for the final stage of its pivotal Phase III clinical trial of a TPM-enhanced cannabidiol soft-gel capsule targeting insomnia in adults. The multi-centre, randomised, double-blind, placebo-controlled ...
Avecho Issues 7.9 Million Unquoted Options Under Employee Incentive Scheme
Aug 27, 2026
Avecho Biotechnology Limited has notified the market of the issue of 7,923,243 unquoted options under its employee incentive scheme, with various exercise prices and expiry dates. The move underscores the company’s continued use of equity-ba...
Avecho hires senior dealmaker to drive CBD insomnia capsule partnerships
Aug 24, 2026
Avecho Biotechnology has appointed senior international biopharmaceutical executive Eve Williamson as a strategic business development consultant to bolster its global partnering and licensing efforts. Williamson, formerly Vice President and Globa...
Avecho Biotechnology Cuts Shareholder Numbers via Small Holding Sale Facility
Aug 12, 2026
Avecho Biotechnology Limited has completed a small holding share sale facility aimed at helping shareholders with low-value holdings exit their positions without brokerage or handling fees. The offer targeted investors whose shares were valued at ...
Avecho secures Japanese patent for TPM-enhanced CBD insomnia capsule
Aug 3, 2026
Avecho Biotechnology has secured a Japanese patent for its proprietary TPM-enhanced cannabidiol capsule, expanding protection for its lead insomnia treatment into the world’s third-largest pharmaceutical market. The patent aligns with existi...
Avecho interim Phase III insomnia result de-risks program and bolsters funding base
Jul 29, 2026
Avecho reported a positive interim analysis from its pivotal Phase III insomnia trial, with an independent board recommending continuation to the originally planned 519 participants and no need to increase the sample size. The safety review found ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.